Disease · MONDO_0007576
Comparisons in its trials46
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 46
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nivolumab vs Placebo: deaths from any cause | 299 of 532 | 162 of 262 | 794 | NCT02743494 | Trial comparisons |
| Nivolumab vs Placebo: serious adverse events | 196 of 532 | 99 of 260 | 792 | NCT02743494 | Trial comparisons |
| Nivolumab Arm vs Active Comparator Arm （Docetaxel/Paclitaxel）: deaths from any cause | 7 of 209 | 5 of 208 | 417 | NCT02569242 | Trial comparisons |
| Nivolumab Arm vs Active Comparator Arm （Docetaxel/Paclitaxel）: serious adverse events | 68 of 209 | 77 of 208 | 417 | NCT02569242 | Trial comparisons |
| Chemoradiation + Cetuximab vs Chemoradiation: serious adverse events | 88 of 162 | 88 of 173 | 335 | NCT00655876 | Trial comparisons |
| Arm I FOLFOX vs Arm II IT: deaths from any cause | 89 of 98 | 94 of 104 | 202 | NCT01498289 | Trial comparisons |
| Chemoradiation and Trastuzumab (Arm 1) vs Chemoradiation (Arm 2): Number of Participants With Any Cardiac Adverse Events Regardless of Attribution | 30 of 95 | 24 of 96 | 191 | NCT01196390 | Trial comparisons |
| Chemoradiation and Trastuzumab vs Chemoradiation: deaths from any cause | 53 of 95 | 55 of 96 | 191 | NCT01196390 | Trial comparisons |
| Chemoradiation and Trastuzumab vs Chemoradiation: serious adverse events | 51 of 95 | 34 of 96 | 191 | NCT01196390 | Trial comparisons |
| Arm I FOLFOX vs Arm II IT: serious adverse events | 7 of 91 | 17 of 98 | 189 | NCT01498289 | Trial comparisons |
| Radiochemotherapy vs Chemotherapy: Safety of Respective Neoadjuvant Therapies. | 79 of 90 | 81 of 91 | 181 | NCT01362127 | Trial comparisons |
| Radiochemotherapy vs Chemotherapy: serious adverse events | 57 of 90 | 41 of 91 | 181 | NCT01362127 | Trial comparisons |
| Radiochemotherapy vs Chemotherapy: Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia. | 22 of 78 | 7 of 78 | 156 | NCT01362127 | Trial comparisons |
| Arm A: Chemo With Radiation Treatment vs Arm B: Pre-Op Chemo + Chemo With Radiation Treatment: serious adverse events | 10 of 63 | 7 of 63 | 126 | NCT00525915 | Trial comparisons |
| Arm A: PCA vs Arm B: TPCA: deaths from any cause | 0 of 44 | 3 of 41 | 85 | NCT00911820 | Trial comparisons |
| Arm A: PCA vs Arm B: TPCA: serious adverse events | 32 of 44 | 36 of 41 | 85 | NCT00911820 | Trial comparisons |
| Arm I (Paclitaxel) vs Arm II (Cixutumumab, Paclitaxel): serious adverse events | 21 of 40 | 23 of 44 | 84 | NCT01142388 | Trial comparisons |
| Group 1 (CPI Naïve) vs Group 2 (CPI Relapse): deaths from any cause | 46 of 61 | 12 of 19 | 80 | NCT04099641 | Trial comparisons |
| Group 1 (CPI Naïve) vs Group 2 (CPI Relapse): Number of Patients With Treatment Emergent Adverse Events (TEAE) | 61 of 61 | 19 of 19 | 80 | NCT04099641 | Trial comparisons |
| Group 1 (CPI Naïve) vs Group 2 (CPI Relapse): serious adverse events | 29 of 61 | 10 of 19 | 80 | NCT04099641 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007576/comparisons